All In Biotech

Drug Trial Radar · NCT06332092

FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma

A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

46

Planned (sponsor's estimate)

Start

Apr 10, 2024

Primary completion

Dec 31, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Fulgent Pharma LLC.Industry
Sponsor type
Industry
First posted
Mar 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this FID-007 Clinical Trial is to compare the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). The main questions it aims to answer are: to evaluate the efficacy, and to characterize the safety and tolerability. Eligible participants will be enrolled and randomized to 1 of 2 arms of FID-007 with fixed-dose Cetuximab in each 28-day cycle.

Conditions

  • Head and Neck Squamous Cell Carcinoma

Interventions

  • FID007Drug

    Patients will receive FID007 via IV infusion at their assigned dose on Days 1, 8, and 15 of each 28-day cycle. Starting from Cycle 2, Cetuximab will be administered every 2 weeks on Days 1 and 15 of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST)Time frame: Through study completion, an average of 1 year

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Highlands Oncology - North Hills

    Fayetteville, Arkansas

  • USC/Norris Comprehensive Cancer Center and Hospital

    Los Angeles, California

  • Moffitt Cancer Center Magnolia Campus

    Tampa, Florida

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • Texas Oncology - Northeast Texas Cancer & Research Institute

    Tyler, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.